Carcinogenesis Advance Access published online on December 24, 2005
Carcinogenesis, doi:10.1093/carcin/bgi329
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
* To whom correspondence should be addressed. Peroxisome proliferators, such as lipid-lowering fibrate drugs, are agonists for the peroxisome proliferator-activated receptor
Received October 3, 2005
Revised November 12, 2005
Accepted December 20, 2005
CARCINOGENESIS
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor
Keiichirou Morimura 1,
Connie Cheung 1,
Jerrold M. Ward 2,
Janardan K. Reddy 3,
and
Frank J. Gonzalez 1 *
to Wy-14,643-induced liver tumorigenesis
2 Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
3 Department of Pathology, Northwestern University School of Medicine, Chicago, IL
Frank J. Gonzalez, E-mail: fjgonz{at}helix.nih.gov
Abstract 
(PPAR). Sustained activation of PPAR leads to the development of liver tumors in rodents. Paradoxically, humans appear to be resistant to the induction of peroxisome proliferation and development of liver tumors by peroxisome proliferators. To examine the species differences in response to peroxisome proliferators, a PPAR humanized mouse (hPPAR) was generated, in which the human PPAR was expressed in liver under control of the Tet-Off system. To evaluate the susceptibility of hPPAR mice to peroxisome proliferator-induced hepatocarcinogenesis, a long-term feeding study of Wy-14,643 was carried out. hPPAR and wild-type (mPPAR) mice were fed either a control diet or one containing 0.1% Wy-14,643 for 44 and 38 weeks, respectively. Gene expression analysis for peroxisomal and mitochondrial fatty acid metabolizing enzymes revealed that both hPPAR and mPPAR were functional. However, the incidence of liver tumors including hepatocellular carcinoma was 71% in Wy-14,643 treated mPPAR mice, and 5% in Wy-14,643 treated hPPAR mice. Up-regulation of cell cycle regulated genes such as cyd d1 and Cdks were observed in non-tumorous liver tissue of Wy-14,643 treated mPPAR mice, while p53 gene expression was increased only in the livers of Wy-14,643-treated hPPAR mice. These findings suggest that structural differences between human and mouse PPAR are responsible for the differential susceptibility to the peroxisome proliferator-induced hepatocarcinogenesis. This mouse model will be useful for human cancer risk assessment of PPAR ligands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. E. Foreman, S.-C. Chang, D. J. Ehresman, J. L. Butenhoff, C. R. Anderson, P. S. Palkar, B.-H. Kang, F. J. Gonzalez, and J. M. Peters Differential Hepatic Effects of Perfluorobutyrate Mediated by Mouse and Human PPAR-{alpha} Toxicol. Sci., July 1, 2009; 110(1): 204 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gopinathan, D. B. Hannon, J. M. Peters, and J. P. Vanden Heuvel Regulation of Peroxisome Proliferator-Activated Receptor-{alpha} by MDM2 Toxicol. Sci., March 1, 2009; 108(1): 48 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cheung and F. J. Gonzalez Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 288 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Wolf, T. Moore, B. D. Abbott, M. B. Rosen, K. P. Das, R. D. Zehr, A. B. Lindstrom, M. J. Strynar, and C. Lau Comparative Hepatic Effects of Perfluorooctanoic Acid and WY 14,643 in PPAR-{alpha} Knockout and Wild-type Mice Toxicol Pathol, June 1, 2008; 36(4): 632 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Rosen, B. D. Abbott, D. C. Wolf, J. C. Corton, C. R. Wood, J. E. Schmid, K. P. Das, R. D. Zehr, E. T. Blair, and C. Lau Gene Profiling in the Livers of Wild-type and PPAR{alpha}-Null Mice Exposed to Perfluorooctanoic Acid Toxicol Pathol, June 1, 2008; 36(4): 592 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chopra, J. Hinley, M. B. Oleksiewicz, and J. Southgate Trans-Species Comparison of PPAR and RXR Expression by Rat and Human Urothelial Tissues Toxicol Pathol, April 1, 2008; 36(3): 485 - 495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Andersen, J. L. Butenhoff, S.-C. Chang, D. G. Farrar, G. L. Kennedy Jr, C. Lau, G. W. Olsen, J. Seed, and K. B. Wallace Perfluoroalkyl Acids and Related Chemistries--Toxicokinetics and Modes of Action Toxicol. Sci., March 1, 2008; 102(1): 3 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Peters Mechanistic Evaluation of PPAR{alpha}-Mediated Hepatocarcinogenesis: Are We There Yet? Toxicol. Sci., January 1, 2008; 101(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
Q. Yang, T. Nagano, Y. Shah, C. Cheung, S. Ito, and F. J. Gonzalez The PPAR{alpha}-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPAR{alpha} Toxicol. Sci., January 1, 2008; 101(1): 132 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hellmold, H. Zhang, U. Andersson, B. Blomgren, T. Holland, A.-L. Berg, M. Elebring, N. Sjogren, K. Bamberg, B. Dahl, et al. Tesaglitazar, a PPAR{alpha}/{gamma} Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats Toxicol. Sci., July 1, 2007; 98(1): 63 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. M. Shah, K. Morimura, Q. Yang, T. Tanabe, M. Takagi, and F. J. Gonzalez Peroxisome Proliferator-Activated Receptor {alpha} Regulates a MicroRNA-Mediated Signaling Cascade Responsible for Hepatocellular Proliferation Mol. Cell. Biol., June 15, 2007; 27(12): 4238 - 4247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn Genomic Profiling in Nuclear Receptor-Mediated Toxicity Toxicol Pathol, June 1, 2007; 35(4): 474 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Konig, H. Kluge, K. Haase, C. Brandsch, G. I. Stangl, and K. Eder Effects of Clofibrate Treatment in Laying Hens Poult. Sci., June 1, 2007; 86(6): 1187 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guo, R. A. Jolly, B. W. Halstead, T. K. Baker, J. P. Stutz, M. Huffman, J. N. Calley, A. West, H. Gao, G. H. Searfoss, et al. Underlying Mechanisms of Pharmacology and Toxicity of a Novel PPAR Agonist Revealed Using Rodent and Canine Hepatocytes Toxicol. Sci., April 1, 2007; 96(2): 294 - 309. [Abstract] [Full Text] [PDF]
|
|